Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 Cases (1997-2004)

Journal of the American Veterinary Medical Association

Volumn 231, Issue 10, 2007, Pages 1550-1557

  Kim, Stanley E ^a,b   Liptak, Julius M ^a,c   Gall, Trent T ^a,d   Monteith, Gabrielle J ^a   Woods, J Paul ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b University of Florida College of Veterinary Medicine   (United States)

^c Alta Vista Animal Hospital ^*  (Canada)

^d Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; EPIRUBICIN;

ADJUVANT CHEMOTHERAPY; ANGIOSARCOMA; ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; FEMALE; MALE; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; SPLEEN TUMOR; SPLENECTOMY; SURVIVAL; TIME; TREATMENT OUTCOME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DOG DISEASES; DOGS; EPIRUBICIN; FEMALE; HEMANGIOSARCOMA; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; SPLENECTOMY; SPLENIC NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

ANIMALIA; CANIS FAMILIARIS;

EID: 37349059606     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.231.10.1550     Document Type: Article

References (37)

1. Priester WA, McKay FW. The occurrence of tumors in domestic animals. Natl Cancer Inst Monogr 1980;54:1-210.
2. Oglivie GK, Moore AS. Hemangiosarcoma. In: Oglive GK, Moore AS, eds. Managing the veterinary cancer patient: a practice manual. Trenton, NJ; Veterinary Learning Systems, 1995:367-376.
3. Brown NO, Patnaik AK, MacEwen EG. Canine hemangiosarcoma: retrospective analysis of 104 cases. J Am Vet Med Assoc 1985;186:56-58.
4. Srebernik N, Appleby EC. Breed prevalence and sites of haemangioma and haemangiosarcoma in dogs. Vet Rec 1991;129:408-409.
5. MacEwen GE. Miscellaneous tumors. In: Withrow SJ, MacEwen GE, eds. Small animal clinical oncology. 3rd ed. Philadelphia: WB Saunders Co, 2001;639-646.
6. Wood CA, Moore AS, Gliatto JM, et al. Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991-1993). J Am Anim Hosp Assoc 1998;34:417-421.
7. Johnson KA, Powers BE, Withrow SJ, et al. Splenomegaly in dogs. Predictors of neoplasia and survival after splenectomy. J Vet Intern Med 1989;3:160-166.
8. Prymak C, McKee LJ, Goldschmidt MH, et al. Epidemiologic, clinical, pathologic, and prognostic characteristics of splenic hemangiosarcoma and splenic hematoma in dogs: 217 cases (1985). J Am Vet Med Assoc 1988;193:706-712.
9. Hammer AS, Couto CG, Filppi J, et al. Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma. J Vet Intern Med 1991;5:160-166.
10. Sorenmo KU, Jeglum KA, Helfand SC. Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide. J Vet Intern Med 1993;7:370-376.
11. Vail DM, MacEwen EG, Kurzman ID, et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res 1995;1:1165-1170.
12. Mauldin GE, Fox PR, Patnaik AK. Doxorubicin-induced cardiotoxicosis. J Vet Intern Med 1992;6:82-88.
13. Ogilvie GK, Richardson RC, Curtis CR, et al. Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors. J Am Vet Med Assoc 1989;195:1584-1587.
14. Ganzina F. 4′-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev 1983;10:1-22.
15. Bertazzoli C, Rovero C, Ballerini L, et al. Experimental systemic toxicology of 4′-epidoxorubicin, a new, less cardiotoxic anthracycline antitumor agent. Toxicol Appl Pharmacol 1985;79:412-422.
16. Hortobagyi GN, Yap HY, Kau SW, et al. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol 1989;12:57-62.
17. Lawton PA, Spittle MF, Ostrowski MJ, et al. A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma. Clin Oncol (R Coll Radiol) 1993;5:80-84.
18. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 1993;19:197-228.
19. Vonderhaar MA. Comparison of doxorubicin and epirubicin in a clinical trial of dogs with multicentric malignant lymphoma. Vet Cancer Soc Newsl 1994;18:8-9.
20. National Cancer Institute. Common toxicity criteria, version 2.0. National Cancer Institute/Cancer Therapy Evaluation Program Web site. March 23, 1998. Available at: ctep.cancer.gov/reporting/ctc.html. Accessed Jun 30, 2006.
21. Sorenmo KU, Baez JL, Clifford CA, et al. Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma. J Vet Intern Med 2004;18:209-213.
22. Ogilvie GK, Powers BE, Mallinckrodt CH, et al. Surgery and doxorubicin in dogs with hemangiosarcoma. J Vet Intern Med 1996;10:379-384.
23. Sorenmo K, Duda L, Barber L, et al. Canine hemangiosarcoma treated with standard chemotherapy and minocycline. J Vet Intern Med 2000;14:395-398.
24. Chu E, DeVita VT. Principles of cancer management: chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA, ed. Cancer: principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins, 2001;289-306.
25. Coukell AJ, Faulds D. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer. Drugs 1997;53:453-482.
26. Veterinary Co-operative Oncology Group. Veterinary Co-operative Oncology Group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats. Vet Comp Oncol 2004;2:194-213.
27. Ogilvie GK, Reynolds HA, Richardson RC, et al. Phase II evaluation of doxorubicin for treatment of various canine neoplasms. J Am Vet Med Assoc 1989;195:1580-1583.
28. Speyer J, Wasserhelt C. Strategies for reduction of anthracycline cardiac toxicity. Semin Oncol 1998;25:525-537.
29. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-905.
30. Selting KA, Lana SE, Ogilvie GK, et al. Cardiac troponin I in canine patients with lymphoma and osteosarcoma receiving doxorubicin: comparison with clinical heart disease in a retrospective analysis. Vet Comp Oncol 2004;2:142-156.
31. Grindem CB, Breitschwerdt EB, Corbett WT, et al. Thrombocytopenia associated with neoplasia in dogs. J Vet Intern Med 1994;8:400-405.
32. Demetri GD, Anderson KC. Disorders of blood cell production in clinical oncology. In: Abeloff MD, Armitage JO, Niederhuber JE, et al, eds. Clinical oncology. Philadelphia: Elsevier, 2004;861-889.
33. Jacquillat C, Chastang C, Tanzer J, et al. Prognostic factors in chronic granulocytic leukemia. A study of 798 cases. Boll Ist Sieroter Milan 1978;57:237-246.
34. Prevost S, Boucher L, Larivee P, et al. Bone marrow hypermetabolism on 18F-FDG PET as a survival prognostic factor in non-small cell lung cancer. J Nucl Med 2006;47:559-565.
35. Parry-Jones N, Matutes E, Gruszka-Westwood AM, et al. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol 2003;120:759-764.
36. Lucroy MD, Madewell BR. Clinical outcome and associated diseases in dogs with leukocytosis and neutrophilia: 118 cases (1996-1998). J Am Vet Med Assoc 1999;214:805-807.
37. Kuntz CA, Dernell WS, Powers BE, et al. Prognostic factors for surgical treatment of soft-tissue sarcomas in dogs: 75 cases (1986-1996). J Am Vet Med Assoc 1997;211:1147-1151.